Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 1

Interventions

pembrolizumab 380Carboplatin 279Specimen Handling 266Nivolumab 257Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 207Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 147atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102fludarabine 97venetoclax 96Capecitabine 94Radiosurgery 93Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × 3-fluorobenzylguanidine × 1 year × Clear all
NCT04724369 2026-04-03

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Phase 3 Active not recruiting
43 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡